GSK R&D cuts to begin in Harlow, say reports
UK drug major GSK will start its programme of R&D cuts at the facility in Harlow, Essex at which it makes pain relief, anxiety and depression drugs.
The firm, which did not respond to in-PharmaTechnolgist’s request for confirmation, has, according to the BBC, begun a 90 day consultation period with the 1,150 staff it employs at the plant that could result in the loss of as many as 380 jobs.
Last Thursday GlaxoSmithKline (GSK) said that it will extend its restructuring programme to try and save an additional $500m by 2012 with cuts to its R&D workforce, confirming several days of media speculation.
Speaking at the time CEO Andrew Witty said that: "A significant proportion of these new cost savings will be generated through reduction of infrastructure," but did not say how many job losses would be involved.
